Drug Profile
Research programme: therapeutics for uro-oncologic disorders - Astellas Pharma/CUOG/CUA
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Canadian Urological Association; Canadian Urological Oncology Group
- Developer Astellas Pharma Canada; Canadian Urological Association; Canadian Urological Oncology Group
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Prostate-cancer in Canada
- 12 Feb 2014 Early research in Prostate cancer in Canada (unspecified route)